FANDOM


Lenalidomide
Lenalidomide

2D structure of the racemate
(R)-lenalidomide

(R)-lenalidomide
(S)-lenalidomide

(S)-lenalidomide

Synonyms

CC-5013, CDC-501, CDC-5013, ENMD-0997, IMiD-3

Brand names

Revlimid

IUPAC name

IUPAC
(3RS)-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione

ChemSpider

187515

DrugBank

DB00480

PubChem

216326

CIF fields

InChI

InChI
1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)

InChIKey

InChIKey
GOTYRUGSSMKFNF-UHFFFAOYSA-N

SMILES

SMILES
NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
(Jmol 3D structure)

Formula

C13H13N3O3

Mol. mass

259.2606 g/mol

MeSH

C467567


Lenalidomide an immunomodulatory drug (IMiD) that is almost identical in its pharmacology to its class prototype, thalidomide with immunomodulatory and antiangiogenic effects. It is generally used in the treatment of myelodysplastic syndrome and multiple myeloma (in the later indication is the combined with dexamethasone). Compared to thalidomide its immunomodulatory/antiangiogenic effects are more powerful and its side effects tend to be less problematic, especially its potential for causing peripheral neuropathy (which can and often is at least partially permanent) and drowsiness.[1]


External linksEdit

Reference listEdit

  1. Rang, HP; Dale, MM; Ritter, JM; Flower, RJ; Henderson, G (2012). "Chapter 55: Anticancer drugs". Rang and Dale's Pharmacology (7th ed. ed.). London, UK: Churchill Livingstone. p. 685. ISBN 978-1-4377-1933-8. 

Ad blocker interference detected!


Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.